Phaseline

Targets › ANO1

ANO1 (Anoctamin-1): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 2; Other, Gastroenterology; next expected readout Dec 2026.

Calcium-activated chloride channel (CaCC). Plays a role in transepithelial anion transport and smooth muscle contraction. (UniProt, Q5XXA6)

Open in Phaseline: the race on ANO1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Napo PharmaceuticalsCrofelemer
Cystic fibrosis transmembrane conductance regulator inhibitor; Anoctamin-1 blocker
CFTR, ANO1Phase 2Microvillus Inclusion DiseaseDec 2026
Napo TherapeuticsCrofelemer
Cystic fibrosis transmembrane conductance regulator inhibitor; Anoctamin-1 blocker
CFTR, ANO1Phase 2Short Bowel SyndromeMar 2027

Conditions

Microvillus Inclusion Disease (1) Short Bowel Syndrome (1)

Modalities

small molecule (2)

Companies

Napo Pharmaceuticals (1) Napo Therapeutics (1)

Related targets

CFTR (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.